To evaluate the effect of blocking redox-dependent reactions with C118 in wild-type KRAS on oncogenic HRASG12V-driven tumorigenesis, we monitored tumor growth of oncogenic HRASG12V-transformed cells upon replacing the endogenous wild-type KRAS protein with the C118S mutant version. Here, KRAS is linked to neoplasm.